Quintrio
Home

Stock overview

Compugen Ltd

CGEN

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

Last trade $2.03
Day change -$0.015 (-0.74%)
Day range $1.99 – $2.05
Volume 135,282
Market cap $193M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for CGEN.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for CGEN.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Compugen (CGEN) Q3 2026 Earnings Call Transcript

Compugen reported Q3 2026 results with revenue of $3.8 million and net loss of $5.8 million. The company completed enrollment in its MAIA-Ovarian trial for COM701 with data expected by end of Q1 2027. Partnered programs with AstraZeneca (rilvegostomig) and Gilead (GS-0321) continue advancing, with rilvegostomig in 12 Phase III trials. The company introduced UnigenX, expanding its discovery platform into tumor-associated antigens for T-cell engagers. Cash runway extends into 2029 with $117.5 million in cash and equivalents.

Zacks Investment Research

Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Beats Revenue Estimates

Nuvation Bio reported a quarterly loss of $0.12 per share, missing the consensus estimate of $0.11 loss, representing a -9.09% earnings surprise. However, the company exceeded revenue expectations with $44.95 million, surpassing estimates by 32.33% and showing 242% year-over-year growth. The stock has underperformed significantly, down 47.7% year-to-date versus the S&P 500's 10.6% gain. Zacks assigned the stock a Hold rating (Rank #3) with mixed estimate revision trends.

Zacks Investment Research

BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates

BioMarin Pharmaceutical (BMRN) reported quarterly earnings of $0.23 per share, significantly beating the consensus estimate of a loss of $0.09 per share, representing a +355.56% earnings surprise. Revenue reached $1.02 billion, slightly missing estimates by 0.23%. The company has surpassed EPS estimates three times over the last four quarters. However, BMRN shares have underperformed the market, down 1.6% year-to-date versus the S&P 500's 10.7% gain. The stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revision trends.

Zacks Investment Research

FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease

Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.